Holen Sie sich die Stockscreener-App
3.00
1.35%
0.04
Schlusskurs vom Vortag:
$2.96
Offen:
$3
24-Stunden-Volumen:
867.62K
Relative Volume:
1.04
Marktkapitalisierung:
$124.93M
Einnahmen:
$123.87M
Nettoeinkommen (Verlust:
$62.49M
KGV:
1.7969
EPS:
1.6695
Netto-Cashflow:
$-87.53M
1W Leistung:
-11.50%
1M Leistung:
-5.06%
6M Leistung:
-14.53%
1J Leistung:
-32.89%
1-Tages-Spanne:
$2.91
$3.095
1-Wochen-Bereich:
$2.86
$3.45
52-Wochen-Spanne:
$2.71
$7.34
Agenus Inc Stock (AGEN) Company Profile
Firmenname
Agenus Inc
Sektor
Branche
Telefon
781-674-4410
Adresse
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
3.00 | 124.93M | 123.87M | 62.49M | -87.53M | 1.6695 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-07-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-02-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-28 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-04-22 | Eingeleitet | B. Riley FBR | Buy |
| 2016-10-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | Bestätigt | Maxim Group | Buy |
| 2016-03-11 | Hochstufung | Maxim Group | Hold → Buy |
| 2015-12-16 | Eingeleitet | Jefferies | Buy |
| 2015-10-27 | Herabstufung | Maxim Group | Buy → Hold |
| 2015-07-27 | Bestätigt | MLV & Co | Buy |
| 2015-06-11 | Eingeleitet | Oppenheimer | Outperform |
| 2015-01-12 | Bestätigt | Maxim Group | Buy |
| 2015-01-09 | Bestätigt | MLV & Co | Buy |
| 2015-01-09 | Bestätigt | Maxim Group | Buy |
| 2014-12-19 | Bestätigt | Maxim Group | Buy |
| 2014-05-08 | Bestätigt | Maxim Group | Buy |
| 2014-03-14 | Bestätigt | MLV & Co | Buy |
| 2013-10-08 | Bestätigt | Maxim Group | Buy |
| 2012-01-05 | Eingeleitet | William Blair | Outperform |
| 2011-12-01 | Eingeleitet | Global Hunter Securities | Buy |
Alle ansehen
Agenus Inc Aktie (AGEN) Neueste Nachrichten
Agenus Inc (AGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Agenus Inc (AGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Agenus Inc (AGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Agenus Inc (AGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Agenus Inc (AGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
AGEN Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Agenus Inc (AGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Agenus Inc (AGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Agenus Inc (AGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Agenus Inc (AGEN) Institutional Confidence - TradingKey
Are options traders betting on a big move in Agenus stock? - MSN
Agenus annual meeting: BOT/BAL leads cancer drug push as balance sheet improves - MSN
Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves - Yahoo Finance
Agenus (NASDAQ: AGEN) pays Dr. Garo Armen salary in stock grant - Stock Titan
Why is Agenus (AGEN) down 9.6% since last earnings report? - MSN
Agenus Inc. (AGEN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report? - Yahoo Finance
AGEN Early Access Revenues Signal a New Path Ahead of Approval - TradingView
Is Agenus Stock a Hold Amid Valuation and Funding Risks? - Yahoo Finance
AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC - TradingView
Agenus Inc. (AGEN) Latest Press Releases & Corporate News - Yahoo Finance
Agenus Announces Virtual 2026 Annual Shareholders Meeting - Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - TMX Newsfile
Garo H. Armen of Agenus (NASDAQ: AGEN) receives 4,644-share stock salary grant - Stock Titan
AGEN Stock Price, Quote & Chart | AGENUS INC (NASDAQ:AGEN) - ChartMill
Agenus Inc.Common Stock (NQ: AGEN - FinancialContent
AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential? - TradingView
How Agenus' Pipeline Progress Unlock Its Next Growth Phase - TradingView
Agenus: Weighing The Clinical Progress Against The Company's Cash (NASDAQ:AGEN) - Seeking Alpha
BOT+BAL Demonstrates Durable Immune Benefit in Advanced Melanoma – Agenus - Oncodaily
Agenus reports melanoma trial data for checkpoint therapy By Investing.com - Investing.com South Africa
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026 - BioSpace
AI model identifies colorectal cancer patients likely to respond - Investing.com UK
Agenus reports melanoma trial data for checkpoint therapy - Investing.com UK
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC - 01net
New melanoma drug combo sees 42% of patients alive at 2 years - Stock Titan
AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell? - TradingView
Agenus (AGEN) chief takes 4,540 common shares as salary - Stock Titan
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer - BioSpace
Agenus (AGEN) price target decreased by 32.61% to 15.81 - MSN
Finanzdaten der Agenus Inc-Aktie (AGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):